Alzamend Neuro (ALZN)
(Delayed Data from NSDQ)
$2.02 USD
-0.01 (-0.49%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $2.01 -0.01 (-0.50%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Alzamend Neuro, Inc falls in the month of April.
All items in Millions except Per Share data.
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 5 | 14 | 2 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 0 | 1 | 2 |
Total Current Assets | 0 | 6 | 14 | 3 | 2 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1 | 6 | 15 | 3 | 2 |
Liabilities & Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 3 | 1 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 3 | 1 | 1 | 1 |
Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 51 | 62 | 57 | 34 | 28 |
Retained Earnings | -54 | -44 | -29 | -17 | -12 |
Other Equity | 0 | -15 | -15 | -15 | -15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -3 | 3 | 13 | 2 | 1 |
Total Liabilities & Shareholder's Equity | 1 | 6 | 15 | 3 | 2 |
Total Common Equity | -3 | 3 | 13 | 2 | 1 |
Shares Outstanding | 0.70 | 0.60 | 0.60 | NA | NA |
Book Value Per Share | -3.70 | 5.08 | 22.25 | 0.00 | 0.00 |
Fiscal Year End for Alzamend Neuro, Inc falls in the month of April.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 0 | 0 | 0 | 2 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 1 | 1 |
Total Current Assets | NA | 0 | 1 | 1 | 2 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 1 | 1 | 1 | 3 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 4 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 4 | 4 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3 | 5 | 4 | 3 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 51 | 49 | 63 | 62 |
Retained Earnings | NA | -54 | -53 | -51 | -48 |
Other Equity | NA | 0 | 0 | -15 | -15 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -3 | -4 | -3 | 0 |
Total Liabilities & Shareholder's Equity | NA | 1 | 1 | 1 | 3 |
Total Common Equity | 0 | -3 | -4 | -3 | 0 |
Shares Outstanding | 0.80 | 0.70 | 0.70 | 0.60 | 0.60 |
Book Value Per Share | 0.00 | -3.70 | -6.09 | -4.47 | -0.18 |